Streetbeat News

FBLG

FibroBiologics Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

2.16

Mkt cap

76M

Volume

99K

High

2.19

P/E Ratio

-3.98

52-wk high

46.00

Low

2.05

Div yield

N/A

52-wk low

1.08

FibroBiologics, Inc. has filed a patent application for a cell-based therapeutic method to treat splenomegaly, expanding its portfolio of over 160 patents. This development highlights the company's focus on fibroblast-based treatments for chronic diseases.

Portfolio Pulse from

November 19, 2024 | 2:30 pm

FibroBiologics, Inc. has filed a patent application for methods using fibroblasts to reduce blood clots associated with IBMIR in cell-based therapies. This development could enhance the company's therapeutic offerings.

Portfolio Pulse from

November 14, 2024 | 2:30 pm

FibroBiologics has reported its third quarter 2024 financial results and provided a corporate update. The company is preparing for a Phase 1/2 clinical trial in Australia for its fibroblast-based spheroids product candidate, CYWC628, aimed at treating diabetic foot ulcers, with plans to start in Q2 2025.

Portfolio Pulse from

November 12, 2024 | 9:30 pm

Wall Street analysts have initiated coverage on several companies with a bullish outlook. NANO Nuclear Energy, FibroBiologics, Invivyd, and Carisma Therapeutics received Buy ratings with significant price targets, indicating potential upside.

Portfolio Pulse from Avi Kapoor

October 30, 2024 | 4:05 pm

HC Wainwright & Co. has initiated coverage on FibroBiologics with a Buy rating and set a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:45 pm

FibroBiologics has announced successful results for its Artificial Thymus Organoid, which demonstrated over 50 days of functionality post-transplant and the production of diverse, mature T cells. This development could have significant implications for the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 1:16 pm

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for FibroBiologics (NASDAQ:FBLG) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:44 pm

FibroBiologics has partnered with Charles River to develop and manufacture fibroblast cell-based therapies for chronic diseases. This collaboration includes CGMP production for a diabetic foot ulcer clinical trial starting in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:34 pm

FibreBiologics shares rose following the issuance of a European patent for their fibroblast delivery of tumor inhibitory agents.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:41 pm

FibroBiologics has been granted a European patent for its fibroblast delivery system of tumor inhibitory agents, potentially enhancing its market position in cancer treatment technologies.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 1:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.